<DOC>
	<DOC>NCT00788294</DOC>
	<brief_summary>The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.</brief_summary>
	<brief_title>Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously</brief_title>
	<detailed_description />
	<criteria>Generally healthy BMI of 1830 kg/m2 more than 50 kg bodyweight. Pregnant exposure to biologic type drugs within the last 3 months history of allergic or anaphylactic reaction to a biologic drug use of tobacco or nicotine containing products that is more than what is in 5 cigarettes per day excessive alcohol use.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Pharmacokinetics tanezumab subcutaneous bioavailability intravenous Japanese subjects</keyword>
</DOC>